Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft
- 198 Downloads
The goal of this project was to demonstrate the feasibility of coupling the indirect ophthalmoscope laser delivery system with the 690 nm wavelength diode laser used to perform photodynamic therapy (PDT) in the treatment of retinoblastoma.
For phase 1, a total of six pigmented rabbits were treated with the indirect laser delivery system. The laser source was provided by the Lumenis Opal 690 nm laser unit, delivered through a 810 nm Indirect ophthalmoscope headpiece and a hand-held 28-diopter indirect lens (1.0 mm spot size). Four rabbits received intravenous verteporfin at doses of 0.43 or 0.86 mg/kg, and two rabbits did not receive verteporfin (controls). A second phase of the study involved eight rabbits using a retinoblastoma xenograft to determine the effect of indirect PDT on subretinal tumors.
For phase 1, a total of 20 laser treatments were performed in the right eyes of six rabbits. Laser power levels ranged between 40 and 150 mW/cm2 and treatment duration ranged between 1 and 3 min. In the four rabbits that received verteporfin, focal retinal scars were noted at 40 mW/cm2 and higher power levels. In the two control rabbits that did not receive verteporfin, thermal burns were confirmed at 75 mW/cm2 and higher power levels. Histopathology showed focal retino-choroidal scars at the site of PDT treatment, without evidence of generalized ocular damage. Using the retinoblastoma xenograft, the indirect PDT system was shown to cause areas of tumor necrosis on histopathology.
The results of this pre-clinical study suggest verteporfin may be activated in the rabbit retina with the indirect delivery system and the 690 nm laser unit (i.e., Indirect PDT). Using verteporfin, treatment effects were observed at 40–50 mW/cm2 in the rabbit retina, while photocoagulation was achieved at 75 mW/cm2 and higher power levels. Fundoscopic and histopathologic examination of treated areas showed circumscribed areas of retinal damage and a lack of generalized ocular toxicity, suggesting that this modality may represent a safe and localized method for treating intraocular retinoblastoma.
KeywordsPhotodynamic therapy Retinoblastoma Laser treatment Indirect ophthalmoscope Xenograft
Research to Prevent Blindness and the Las Madrinas Endowment in Experimental Therapeutics.
Compliance with ethical standards
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval: “All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”
University of California, Los Angeles: “All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.”
- 12.Iridex (2014) Laser Indirect Ophthalmoscope (LIO) by Iridex. http://www.iridex.com/Portals/0/pdf/LT0011_LIO.pdf. Accessed 15 Jun 2015
- 19.Zhu D, Berry JL, Ediriwickrema L, Wong K, Lee TC, Murphree AL, Kim JW, Jubran R (2015) Long-term outcomes of group B eyes in patients with retinoblastoma treated with short-course chemoreduction: experience from Children’s hospital Los Angeles/University of Southern California. Ocul Oncol Pathol 2(2):105–111CrossRefPubMedPubMedCentralGoogle Scholar